Repros expects to report results for Phase 2 vaginal Proellex study in 1Q13 Sees fully enrolling 1 year Dexa study in Q1. Expects to request Androxal pre-NDA meeting with FDA for 1Q14 in 4Q13. Comments from slides that will be presented at the 2013 Biotech Showcase Conference.
News For RPRX From The Last 14 Days
Check below for free stories on RPRX the last two weeks.